Not for release, publication or distribution, in whole or in part directly or
indirectly, in Australia, Canada, the Hong Kong Special Administrative Region of
the People's Republic of China, Japan or the United States (or any other
jurisdiction in which the release, publication or distribution would be
unlawful). This announcement does not constitute an offer of any of the
securities described herein  

Reference is made to previous announcements regarding the Rights Issue of up to
1,237,508,259 new shares in SoftOx Solutions AS (the "Company"). 

The subscription period for the Rights Issue expired on 23 August 2024 at 16:30
hours (CEST). Preliminary results indicate that the Company has received
subscriptions for a total of 1.249.544.633 Offer Shares, with gross proceeds of
NOK 24.990.892,66 thus, the Right Issue will be fully subscribed.

The underwriters are entitled to subscribe for shares in the Right Issue. The
subscription period for the underwriters ends on the 30th of August 2024 at
16:30 hours (CEST).

The final allocation of the Offer Shares is expected to take place on or about 2
September 2024. The final result of the Rights Issue will be published shortly
thereafter, and letters regarding allocation of Offer Shares and the
corresponding subscription amount to be paid by each subscriber, are expected to
be distributed on or about 2 September 2024. The payment date for the Offer
Shares will be on or about 5 September 2024 and delivery and listing and start
trading on Euronext Growth of the Offer Shares are expected on or about 7
September 2024. 

For any questions please contact:  

Geir Almås, Chair of SoftOx Solutions AS  

Mail: ir@soft-ox.com  

Phone: Geir Almås: (+47) 977 59 071  

About SoftOx Solutions AS  

SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes: the holding
company SoftOx Solutions AS, the Malmö subsidiary Water Innovation AB, and
subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is
developing a highly effective antimicrobial solution for use in biofilm, viral
and antimicrobial resistant infections. The patent-protected technology is based
on extensive research and development in partnership with leading Nordic
research institutes. 

For more information on SoftOx, visit www.soft-ox.com 

IMPORTANT NOTICES  

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. The
distribution of this announcement and other information may be restricted by law
in certain jurisdictions. Copies of this announcement are not being made and may
not be distributed or sent into any jurisdiction in which such distribution
would be unlawful or would require registration or other measures. Persons into
whose possession this announcement or such other information should come are
required to inform themselves about and to observe any such restrictions. The
securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and accordingly may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act and in accordance with applicable U.S. state securities laws.
The Company does not intend to register any part of the offering or their
securities in the United States or to conduct a public offering of securities in
the United States. Any sale in the United States of the securities mentioned in
this announcement will be made solely to "qualified institutional buyers" as
defined in Rule 144A under the Securities Act. In any EEA Member State, this
communication is only addressed to and is only directed at qualified investors
in that Member State within the meaning of the Prospectus Regulation, i.e., only
to investors who can receive the offer without an approved prospectus in such
EEA Member State. The expression "Prospectus Regulation" means Regulation
2017/1129 as amended together with any applicable implementing measures in any
Member State. This communication is only being distributed to and is only
directed at persons in the United Kingdom that are (i) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net
worth entities, and other persons to whom this announcement may lawfully be
communicated, falling within Article 49(2)(a) to (d) of the Order (all such
persons together being referred to as "relevant persons"). This communication
must not be acted on or relied on by persons who are not relevant persons. Any
investment or investment activity to which this communication relates is
available only for relevant persons and will be engaged in only with relevant
persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so. Matters discussed in this announcement may constitute
forward-looking statements. Forward-looking statements are statements that are
not historical facts and may be identified by words such as "believe", "expect",
"anticipate", "strategy", "intends", "estimate", "will", "may", "continue",
"should" and similar expressions. The forward-looking statements in this release
are based upon various assumptions, many of which are based, in turn, upon
further assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its control.
Actual events may differ significantly from any anticipated development due to a
number of factors, including without limitation, changes in investment levels
and need for the Company's services, changes in the general economic, political
and market conditions in the markets in which the Company operate, the Company's
ability to attract, retain and motivate qualified personnel, changes in the
Company's ability to engage in commercially acceptable acquisitions and
strategic investments, and changes in laws and regulation and the potential
impact of legal proceedings and actions. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The Company does not provide any guarantees that the
assumptions underlying the forward-looking statements in this announcement are
free from errors nor does it accept any responsibility for the future accuracy
of the opinions expressed in this announcement or any obligation to update or
revise the statements in this announcement to reflect subsequent events. You
should not place undue reliance on the forward-looking statements in this
document. The information, opinions and forward-looking statements contained in
this announcement speak only as at its date, and are subject to change without
notice. The Company does not undertake any obligation to review, update,
confirm, or to release publicly any revisions to any forward-looking statements
to reflect events that occur or circumstances that arise in relation to the
content of this announcement. Neither of the Company, the Manager nor any of
their respective affiliates makes any representation as to the accuracy or
completeness of this announcement and none of them accepts any responsibility
for the contents of this announcement or any matters referred to herein. This
announcement is for information purposes only and is not to be relied upon in
substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities in the Company. Neither the
Company, the Manager nor any of their respective affiliates accepts any
liability arising from the use of this announcement.